Search Results
Showing Results for safety
Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.
At EAN 2025, Prof. Moccia shared his perspective on the evolving multiple sclerosis McDonald criteria, the role of advanced imaging and fluid biomarkers, and the exciting innovations reshaping MS diagnosis and management.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode of Visionary Voices, Dr Anthony Caggiano, Chief Medical Officer at Cognition Therapeutics, joins us to explore how biomarkers are transforming our understanding of Alzheimer’s disease, from diagnosis and disease progression to drug development and the future of clinical care.
Broadest approval to date in generalized myasthenia gravis The FDA approval of nipocalimab for generalized myasthenia gravis (gMG) introduces a targeted therapy within a validated class, offering the potential for durable disease control across the broadest patient population to date. ...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...
n this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.
In this Q&A, Dr Andy Liu, Associate Professor of Neurology at Duke University School of Medicine, discusses his presentation on the clinical use of lecanemab in Alzheimer’s disease. Drawing on real-world experience and findings from the 2022 CLARITY AD study, Dr Liu explores the treatment’s benefits, challenges in daily practice and the importance of patient-centred care in this evolving therapeutic landscape.
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...
The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.
The FDA has approved tenecteplase (TNKase) for the treatment of acute ischemic stroke (AIS) in adults, marking the first new stroke-specific thrombolytic approval in nearly three decades. Administered as a single five-second intravenous bolus, tenecteplase allows for faster administration compared to the current standard of care alteplase, which is administered as a bolus-plus-infusion regimen.
The first prenatal treatment for spinal muscular atrophy showed promise in a single case report.
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.
Rotterdam (ka). ‘Towards a better headache treatment for everyone’ - The ambitious motto of achieving better headache treatment for everyone was at the centre of the 18th European Headache Congress in Rotterdam. The top-class conference is regarded as an international platform for scientific exchange on the subject of headaches. Confidently chaired by Prof Antoinette Maassen van den Brink, Rotterdam and Prof Jan Versijpt, Brussels, the EHC 2024 Congress was a complete success with around 2,200 participants.
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare, autoimmune neurological disorder in which peripheral nerve demyelination typically results in weakness, impaired limb sensation, fatigue and pain.1–4 CIDP may adversely affect activities of daily living, with a substantial impact on functional ...
The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
